Search

Displaying results 1481 - 1490 of 4599 in total
  1. Drug

    Amrubicin

    go.drugbank.com/drugs/DB06263
    Investigational

    In 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC. … Since January 2005, Amrubicin has been marketed by Nippon Kayaku, a Japanese pharmaceutical firm focused on oncology, which licensed Japanese marketing rights from Dainippon Sumitomo, the original developer

  2. Drug

    Tetryzoline

    go.drugbank.com/drugs/DB06764
    Approved

    Tetryzoline, also known as tetrahydrozoline, is a derivative of imidazoline with central and peripheral alpha (α)-adrenergic properties. Available since the 1950s, tetryzoline is a selective α1-receptor agonist that is used as an ocular ...

    Mixtures: Up and Up Ultra Itchy Relief, SK Advanced Relief Eye DropsProducts: SK Original Eye Drops, Circle K Eye Drops Redness Reliever
  3. Drug

    Sodium phosphate, monobasic

    go.drugbank.com/drugs/DB09449
    ApprovedInvestigational

    Sodium phosphate is a saline laxative that is thought to work by increasing fluid in the small intestine. It usually results in a bowel movement after 30 minutes to 6 hours.

    Mixtures: UR N-C Urinary Antiseptic, K-Phos No. 2
  4. Drug

    Huperzine B

    go.drugbank.com/drugs/DB03348
    Experimental

    Huperzine B is a novel acetylcholinesterase inhibitor.

  5. Drug

    Copper histidinate

    go.drugbank.com/drugs/DB32041
    Approved

    It was approved by the US FDA in January 2026 for the treatment of pediatric patients with Menkes disease.[L54993,L54998] … Menkes disease is a rare, X-linked recessive disorder caused by pathogenic variants in the ATP7A gene, which encodes a copper transport protein essential for absorbing dietary copper and transporting it

  6. Drug

    Actoxumab

    go.drugbank.com/drugs/DB16376
    Investigational

    Actoxumab is under investigation in clinical trial NCT01241552 (A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)

  7. Drug

    Acipimox

    go.drugbank.com/drugs/DB09055
    ApprovedInvestigational

    Long-term administration is associated with reduced mortality, but unwanted effects limit its clinical use. … Acipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL.

  8. Drug

    Calcium citrate

    go.drugbank.com/drugs/DB11093
    ApprovedInvestigational

    Calcium citrate is a salt typically used as a source of calcium in a variety of over the counter supplements.

    Mixtures: CALCIBON® D 800 UI TABLETAS RECUBIERTAS, CALCIBON® D 800 UI TABLETAS RECUBIERTAS
  9. Drug

    Mirabegron

    go.drugbank.com/drugs/DB08893
    ApprovedInvestigational

    Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, ...

  10. Drug

    Edotreotide gallium Ga-68

    go.drugbank.com/drugs/DB15494
    Approved

    [A185852] Dotatate gallium Ga-68 has lower tumor uptake but this data is highly variable between patients.[A185852] Edotreotide gallium Ga-68 was granted FDA approval on 21 August 2019.[L8597] … [L8603] Edotreotide gallium Ga-68 is indicated for localizing somatostatin receptor positive neuroendocrine tumors by positron emission tomography.